JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

Search

Crinetics Pharmaceuticals Inc

Avatud

SektorTervishoid

38.36 1.75

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.42

Max

38.62

Põhinäitajad

By Trading Economics

Sissetulek

7.3M

-123M

Müük

3.7M

3.9M

Aktsiakasum

-1.29

Kasumimarginaal

-3,161.261

Töötajad

594

EBITDA

20M

-122M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+124.84% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-445M

4B

Eelmine avamishind

36.61

Eelmine sulgemishind

38.36

Uudiste sentiment

By Acuity

14%

86%

26 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 23:53 UTC

Tulu

Naver Posts Weaker First-Quarter Earnings

29. apr 2026, 23:41 UTC

Kuumad aktsiad

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. apr 2026, 23:55 UTC

Tulu

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. apr 2026, 23:54 UTC

Tulu

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. apr 2026, 23:52 UTC

Tulu

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. apr 2026, 23:51 UTC

Tulu

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. apr 2026, 23:22 UTC

Tulu

China Longyuan 1Q Net CNY1.70B, Down 14%

29. apr 2026, 23:22 UTC

Tulu

China Longyuan: Power Generation Down 2.9% as of End-March

29. apr 2026, 23:20 UTC

Tulu

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. apr 2026, 23:20 UTC

Tulu

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss Narrows>000002.SZ

29. apr 2026, 23:18 UTC

Tulu

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. apr 2026, 23:17 UTC

Tulu

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. apr 2026, 23:13 UTC

Tulu

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. apr 2026, 23:12 UTC

Tulu

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. apr 2026, 23:04 UTC

Tulu

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. apr 2026, 23:04 UTC

Tulu

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

124.84% tõus

12 kuu keskmine prognoos

Keskmine 86.43 USD  124.84%

Kõrge 97 USD

Madal 67 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

8

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

26 / 348 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat